Enanta Pharmaceuticals PT Raised to $44.00 at Credit Suisse (ENTA)
Equities researchers at Credit Suisse raised their target price on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from $43.00 to $44.00 in a research report issued on Friday. The firm currently has an “outperform” rating on the stock. Credit Suisse’s price target would suggest a potential upside of 12.27% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at FBR Capital Markets initiated coverage on shares of Enanta Pharmaceuticals in a research note on Thursday. They set an “outperform” rating and a $52.00 price target on the stock. Separately, analysts at Zacks upgraded shares of Enanta Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday. They now have a $47.10 price target on the stock. Finally, analysts at JMP Securities downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $45.82.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 1.53% during mid-day trading on Friday, hitting $39.79. The stock had a trading volume of 269,263 shares. Enanta Pharmaceuticals has a 52 week low of $18.21 and a 52 week high of $46.443. The stock has a 50-day moving average of $39.61 and a 200-day moving average of $38.36. The company has a market cap of $739.4 million and a price-to-earnings ratio of 21.10.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 11th. The company reported $2.61 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.67 by $0.94. The company had revenue of $42.10 million for the quarter, compared to the consensus estimate of $40.83 million. The company’s quarterly revenue was up 2531.3% on a year-over-year basis. Analysts expect that Enanta Pharmaceuticals will post $1.35 EPS for the current fiscal year.
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.